Evidence map›Paper›PMID 40071139›Full record

ReviewCambridge prisms. Precision medicine2025

Harnessing the power of genomics in hypertension: tip of the iceberg?

Hafiz Naderi, Helen R Warren, Patricia B Munroe

Abstract readReview
In one paragraph

Review in Cambridge prisms. Precision medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Hafiz NaderiWilliam Harvey Research Institute, Queen Mary University of London, London, UK.ORCID https://orcid.org/0000-0002-3217-780X
Helen R WarrenWilliam Harvey Research Institute, Queen Mary University of London, London, UK.ORCID https://orcid.org/0000-0003-0511-1386
Patricia B MunroeWilliam Harvey Research Institute, Queen Mary University of London, London, UK.ORCID https://orcid.org/0000-0002-4176-2947

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the blaze of advancing knowledge on its complex genetic architecture, hypertension remains an elusive condition. Genetic studies of blood pressure have yielded bitter-sweet results thus far with the identification of more than 2,000 genetic loci, though the candidate causal genes and biological pathways remain largely unknown. The era of big data and sophisticated statistical tools has propelled insights into pathophysiology and causal inferences. However, new genetic risk tools for hypertension are the tip of the iceberg, and applications of genomic technology are likely to proliferate. We review the genomics of hypertension, exploring the significant milestones in our current understanding of this condition and the progress towards personalised treatment and management for hypertension.

Indexed as

genomicshypertensionprecision medicine

Identifiers

PMID40071139
PMCPMC11894416

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.